TrialSignal
Clinical trial intelligence report
Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab (AVASTIN ®) in Combination With Weekly Paclitaxel Chemotherapy in First Line Treatment Patients With Metastatic Breast Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01745757
Status
COMPLETED
Phase
Observational
Sponsor
UNICANCER
Executive brief
Investment-Ready Snapshot
The COMET study, sponsored by UNICANCER, aimed to validate predictive factors and biological imaging related to the response of metastatic breast cancer patients to Bevacizumab and Paclitaxel. The study enrolled 510 patients and was completed in December 2022. It focused on identifying biomarkers that could help tailor treatments and improve patient outcomes.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01745757
Indication
Metastatic
Modality
monoclonal antibody
Target
Metastatic Breast Cancer
Intervention
Bevacizumab, paclitaxel
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.